Physician profile
Robert Jenkins
NPI 1487071981
$6,458.41
in general payments reported to CMS, 2019-2025
29 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $586 · 2022: $2,028 · 2023: $1,791 · 2024: $1,735 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,550 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,550.14 |
| Education | $294.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,630.70 | 2021-2024 | Calquence, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $1,019.25 | 2022-2024 | Erleada, Darzalex, Imbruvica |
| Janssen Pharmaceuticals, INC | $651.70 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $616.62 | 2022-2024 | Augtyro |
| Daiichi Sankyo INC. | $353.23 | 2022-2024 | Injectafer |
| Beigene USA, INC. | $249.99 | 2021-2024 | Brukinsa |
| Boston Scientific Corporation | $225.47 | 2025 | Infinion 16, General - Pain Management, Wavewriter Alpha Prime 16 |
| Pharmacosmos Therapeutics INC. | $200.53 | 2022-2024 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $132.40 | 2022 | |
| Genentech USA, INC. | $126.00 | 2023 | Venclexta |
| Celgene Corporation | $124.08 | 2021 | |
| Incyte Corporation | $121.50 | 2021 | |
| Glaxosmithkline, LLC. | $121.28 | 2024 | Arexvy |
| Regeneron Healthcare Solutions, INC. | $112.49 | 2024 | Libtayo |
| Genzyme Corporation | $108.35 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $97.43 | 2024 | Fruzaqla |
| Merck Sharp & Dohme LLC | $90.54 | 2022 | |
| Abbvie INC. | $87.95 | 2024 | |
| Eisai INC. | $83.34 | 2022 | |
| Myriad Genetic Laboratories, INC. | $77.25 | 2022 | |
| Aveo Pharmaceuticals, INC. | $66.99 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $26.05 | 2023 | Tazverik |
| Lundbeck LLC | $23.54 | 2024 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.36 | 2025 | Relistor |
| Valinor Pharma, LLC | $22.75 | 2025 | Movantik |
| Avanos Medical | $19.11 | 2025 | Standard Rf Disposables |
| Collegium Pharmaceutical, INC. | $17.72 | 2024 | Xtampza |
| Tonix Medicines, INC. | $15.04 | 2025 | Tonmya |
| Electronic Waveform Lab, INC. | $13.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.